go-v.orgdoi

EGFR genomic alterations in cancer: prognostic and predictive values

Giuseppe Bronte · Frontiers in Bioscience-Elite · 2009

  • DOI 10.2741/296
  • Publisher Frontiers Media
  • Type article
  • Issued 2009

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Frontiers in Bioscience-Elite · Frontiers Media · article · 2009

Abstract

The role of EGFR in cancer development and progression has been recognized for long time in a variety of human malignancies including lung, head and neck, colon, breast, ovary and glioma. Recently its role as a target of antineoplastic agents has also been identified and a variety of EGFR-targeted drugs is already being used in a clinical setting and others are at present under investigation. Many data involving EGFR protein expression are now available for the choice of anti-EGFR monoclonal antibodies in colorectal cancer and with regard to EGFR gene mutations for the choice of tyrosine kinase inhibitors in lung cancer.

Other EGFR-related molecular factors, including the EGFR gene copy number, are currently under investigation. This review summarizes both preclinical and clinical available data regarding EGFR genomic alterations as prognostic and predictive factors.

Open the resolved locator · 10.2741/296

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 00:33 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.2741/296
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.